**LYMNL0145**
Phase III Topical Naloxone Hydrochloride Lotion 0.5% in MF or SS Forms of Cutaneous T-Cell Lymphoma
PI: Kim Soligenix
Sponsor: Elerac Inc.

**LYMNL0143**
Phase II CD11301.003% & 0.06% Gel in Tx of Cutaneous T-Cell Lymphoma(CTCL) Stages IA, IB & IIA
PI: Kim Soligenix
Sponsor: Galderma R&D

**LYMNL0149**
Phase II Optimizing Dosing of Brentuximab Vedotin for Mycosis Fungoides and Lymphomatoid Papulosis
PI: Kim Memorial Sloan Kettering

**LYMNL0142**
Phase II MK-3475 (Pembrolizumab) & Interferon Gamma 1b +/- Immunotherapy in PreviouslyTreated MF/SS
PI: Kim Memorial Sloan Kettering

**LYMNL0138**
Phase I/IIA Cerdulatinib (PRT062070) in Relapsed/Refractory CLL or SLL B-Cell or T-Cell NHL
PI: Kim Portola Pharmaceuticals

**LYMNL0136**
Phase I Duvelisib in Combo w/ Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
PI: Kim Memorial Sloan Kettering

**LYMNL0146**
Phase Ia/Ib TT1-621 Targeting CD47 in Relapsed / Refractory Hematologic Malignancies & Solid Tumors
PI: Kim Memorial Sloan Kettering

**LYMNL0103**
Phase III Safety and Efficacy of E7771 (Denileukin Diftux) in Persistent/Recurrent Cutaneous NHL
PI: Kim Esai Oncology Franchise